KYTHERA Biopharmaceuticals Announces Presentation of Phase 2 Data on Novel Fat Reduction Drug at ASDS Meeting
(BUSINESS WIRE)--Sep 30, 2009 - MEDIA ADVISORY from KYTHERA Biopharmaceuticals:
| What: | Presentation of Phase 2 Data on ATX-101, a
First-in-Class, Novel, Injectable Drug For The Reduction of
Localized Fat
|
| When: | 11:00 a.m. (MST/PDT) Friday, Oct. 2, 2009
(2:00 p.m. Eastern, 1:00 p.m. Central)
|
| Where: | The American Society for Dermatologic
Surgery (ASDS) and
American Society of Cosmetic Dermatology and Aesthetic Surgery (ASCDAS) Joint Annual Meeting, Phoenix, AZ
Scientific Session (CS263) - “You Asked for It”
|
| Why: | In a rapidly growing market of
minimally-invasive, non-surgical facial rejuvenation, the reduction
of facial fat deposits to restore and reshape the jawline remains
one of the largest unmet patient needs. Currently, there are no FDA
approved drugs to reduce excess localized fat.
KYTHERA is developing ATX-101 to address this need. ATX-101 is a first-in-class injectable drug for the reduction of localized fat. The initial application of ATX-101 is for the reduction of submental (under the chin) fat.
|
| On Availability: | KYTHERA CEO Keith Leonard is available to
discuss the Phase 2 data beginning at 12 p.m. Friday.
|
ATX-101 is a first-in-class injectable drug being studied for the reduction of small volumes of fat. It is based on an endogenous compound with unique features including selectivity for adipocytes and rapid clearance. ATX-101 clinical research is focused on reduction of localized fat deposits, including submental fat. KYTHERA has completed two randomized, double-blind, placebo-controlled, Phase 2 studies with ATX-101 in the reduction of submental fat and two Phase 1 pharmacokinetic and histology studies.
About KYTHERA Biopharmaceuticals
KYTHERA is a privately-held biopharmaceutical company that applies the tools of biotechnology to develop innovative prescription therapeutics for aesthetic medicine. KYTHERA has active programs in adipolysis (ATX-101), facial contouring (ATX-104) and pigmentation modulation (ATX-202).
For more information about KYTHERA, please visit the company's Web site at www.kytherabiopharma.com. Data slides highlighting these results will be available online at http://www.kytherabiopharma.com/atx101.html on October 2, 2009 following the live presentation.
Contact: KYTHERA Biopharmaceuticals, Inc.
Erica Bazerkanian, 805-300-9289
inquiry@kytherabiopharma.com
Posted: October 2009
